59 Views | 31 Downloads
Michael A. Dyer, Department of Developmental Neurobiology, MS 323, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-3678, USA, Phone: (901) 595-2257; Fax: (901) 595-3143; michael.dyer@stjude.org
E.S. and M.A.D. designed the study and wrote the paper. S.F. wrote and supervised the protocol. X.C. and B.X. performed all computational analyses. C.B., B.G, V.H., M.O., K.B., J.D. assisted with preclinical animal studies and cell screening. J.E. assisted with molecular analyses. M.C. and A.B. provided pathology review. B.F. performed pharmacokinetic analysis. J.W. performed biostatistics. N.T. and A.S. analyzed drug sensitivity data. A.K. manages the CSTN and assisted with drug screening. X.Z. developed the protein paint visualization. E.R.M., R.K.W., J.D., J.Z., A.P. and M.A.D. contributed to the Pediatric Cancer Genome Project.
We thank Angela McArthur for editing the manuscript.
The authors declare no competing financial interests.
This work was supported by Cancer Center Support (CA21765), grants to M.A.D from the NIH (EY014867, EY018599, and CA168875), and American Lebanese Syrian Associated Charities (ALSAC). M.A.D. was also supported by HHMI, Alex Lemonade Stand, Tully Family and Peterson Foundations. E.S. was supported by the St. Baldrick’s Foundation and the National Pediatric Cancer Foundation (NPCF).
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use